NBRVF — Nabriva Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update
U.S. STOCKS ON THE MOVE-Talkspace, Flora Growth, Grindr Inc
U.S. STOCKS ON THE MOVE-Builders FirstSource, Tenaya Therapeutics, Blue Apron
U.S. STOCKS ON THE MOVE-Taboola, Axsome, Amazon
Nabriva Therapeutics up on promising cystic fibrosis study data
Brief: Nabriva Therapeutics Reports Positive Topline Results From Phase 1 Trial Of Cystic Fibrosis Drug
Nabriva Therapeutics PLC reports results for the quarter ended in September - Earnings Summary
Brief: Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results, Provides Corporate Update
Nabriva Therapeutics PLC expected to post a loss of $4.02 a share - Earnings Preview
Brief: Nabriva Therapeutics Receives Letter From Nasdaq Notifying It Had Regained Compliance
U.S. STOCKS ON THE MOVE-Adobe, Netflix, FTC Solar
Brief: Nabriva Therapeutics Announces Date Of 1-For-25 Reverse Stock Split
Brief: Nabriva Therapeutics completes patient enrollment in Phase 1 Trial of Xenleta® (Lefamulin) in adult patients with cystic fibrosis
Brief: Nabriva Therapeutics Reports Second Quarter 2022 Financial Results And Provides A Corporate Update
U.S. STOCKS ON THE MOVE-Netflix, Kraft Heinz, travel stocks
U.S. STOCKS ON THE MOVE-Cruise stocks, Advent Technologies, Expensify Inc